Navigation Links
Study Results Demonstrate Analytical Treatment Interruption to Assess Antiviral Activity of Argos's Arcelis™ Personalized Immunotherapy for Treatment of HIV Patients, AGS-004, Is Acceptable Strategy for At Least 16 Weeks
Date:5/3/2012

DURHAM, N.C., May 3, 2012 /PRNewswire/ -- Argos Therapeutics Inc. today announced that study results demonstrated that analytical treatment interruption to assess the antiviral activity of Argos's Arcelis™ personalized immunotherapy for the treatment of HIV patients, AGS-004, is an acceptable strategy for at least 16 weeks. Study results were published in the Journal of Medical Virology (84:885–889, 2012).

"Establishing the safety of analytical treatment interruptions of at least 16 weeks is an important step forward in assessing the impact of immunotherapy on viral load control," said Charles Nicolette, Ph.D., chief scientific officer and vice president of research and development of Argos. "Therapeutic vaccines such as AGS-004 have the potential to decrease long-term antiretroviral therapy which has limitations such as drug toxicity, the risk of developing resistance and others. We look forward to advancing our Phase 2b trial of AGS-004 to further demonstrate its efficacy and safety for the treatment of HIV patients."

The potential risks of short-term interruption of antiretroviral therapy in the AGS-004-001 study were assessed in a retrospective subgroup study analyzing data from patients in the strategies for management of anti-retroviral therapy (SMART) study with matched eligibility criteria. The subgroup analysis included 440 of 2,720 on the drug conservation (DC) arm and 436 of 2,752 on the viral suppression (VS) arm that matched the AGS-004-001 inclusion criteria and were used in the SMART subgroup analysis. In the first 16 weeks following randomization into the SMART study there were no deaths in either subgroup.  There were two AIDS-related events in the DC subgroup and one in the VS subgroup, making the overall risk of AIDS related events two per 100 person years (0.005%) and one per 100 person years (0.002%) in the two subgroups, respectively.  There were 6/440 subjects (1.4%) in the DC subgroup and 4/436 subjects (0.92%) in the VS subgroup who experienced grade 2 adverse events defined as AIDS-related event, a cardiovascular disease, renal or hepatic event, cancer or death.

About the Arcelis™ Technology
Arcelis is Argos's proprietary technology for personalizing RNA-loaded dendritic cell immunotherapies. This platform is based on optimizing a patient´s own (autologous) dendritic cells to trigger a tumor- or pathogen-specific immune response. To address the challenge of the unique genetic profile of each patient's disease and the genetic mutations of that disease, Argos loads the autologous dendritic cells with a sample of messenger RNA ("mRNA") isolated from the patient´s disease. Through this process, dendritic cells can potentially prime immune responses to the entire antigenic repertoire, resulting in an immunotherapeutic that is fully personalized for each patient's disease.

About Argos Therapeutics
Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis™ technology platform. Using biological components from each patient, Arcelis-based immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease. Argos' most advanced product candidates include AGS-003 for the treatment of metastatic renal cell carcinoma, or mRCC, and AGS-004 for the treatment of HIV. 

Contact:

David Schull or Andreas Marathovouniotis
Russo Partners LLC
(212) 845-4271 or (212) 845-4235
david.schull@russopartnersllc.com or andreas.marathis@russopartnersllc.com

Jeff Abbey
Argos Therapeutics
(919) 287-6308
jabbey@argostherapeutics.com


'/>"/>
SOURCE Argos Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... , Feb. 22, 2017 Henry ... an exclusive distribution agreement with Rijuven, which develops ... diagnostic device to medical practitioners. ... electrocardiogram (ECG) and heart sound signals, transmits real-time ... and offers cloud-based analysis to help physicians provide ...
(Date:2/22/2017)... Calif. , Feb. 22, 2017  Bioness, Inc., ... therapies, today announced the first series of successful StimRouter ... at Radboud University Medical Center (Nijmegen, Netherlands ... ( Cork, Ireland ), and Kliniek Park ... the successful launch continuing, Bioness plans to further support ...
(Date:2/22/2017)... , Feb. 22, 2017 Oncternal Therapeutics, ... for both rare and common malignancies, today announced ... financing. The company intends to use the proceeds ... TK216, and to advance preclinical development of a ... Cirmtuzumab is a first-in-class anti-ROR1 monoclonal antibody being ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... ... newest advanced absorption cannabidiol (CBD) serum, “NANOCALM 300” Microemulsified Hemp Extract. This ... instant absorption from the mouth into the bloodstream. Far outpacing the ...
(Date:2/22/2017)... ... 22, 2017 , ... The Centers for Medicare & Medicaid ... in Delaware, New Jersey, Pennsylvania and West Virginia prepare for and participate in ... Act of 2015 (MACRA). , This technical assistance, authorized and funded under ...
(Date:2/22/2017)... NJ (PRWEB) , ... February 22, 2017 , ... ... healthcare communications company, launched a new media platform connecting healthcare technology professionals and ... will be followed by a quarterly publication starting on March 1, announced Michael ...
(Date:2/22/2017)... ... February 22, 2017 , ... Pet obesity in the U.S. continued ... according to the Association for Pet Obesity Prevention (APOP). During the ninth annual survey, ... such as the benefits of corn and grains, value of raw and organic diets, ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... so many different solutions on the market, it is easy to start feeling ... Premier Locksmith offers a complimentary security consultation. , Home Security Hardware Choices, ...
Breaking Medicine News(10 mins):